Overview

Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

Status:
Completed
Trial end date:
2017-04-26
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to prove the efficacy and safety of Fexinidazole as an oral treatment for human african trypanosomiasis in advanced stage. The Fexinidazole is compared to reference treatment NECT. The trial will try to demonstrate that Fexinidazole is not inferior to NECT treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Drugs for Neglected Diseases
Treatments:
Eflornithine
Nifurtimox